CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action.
Kimble
E
E
Research Department, Ciba-Geigy Corp., Summit, NJ 07901, USA.
Kowalski
T
T
Peters
P
P
Lee
W
W
Koehler
J
J
Raychaudhuri
A
A
Chertock
H
H
Blancuzzi
V
V
van Duzer
J
J
D000818:Animals; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007546:Isoquinolines / Q000494:pharmacology* / Q000633:toxicity; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D010998:Pleurisy / Q000139:chemically induced / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D044005:Tetrahydroisoquinolines
C097664:CGS 26529; D007546:Isoquinolines; D016859:Lipoxygenase Inhibitors; D044005:Tetrahydroisoquinolines; C063449:zileuton; D006918:Hydroxyurea